KR102822365B1 - 유로리틴 화합물을 포함하는 조성물 - Google Patents

유로리틴 화합물을 포함하는 조성물 Download PDF

Info

Publication number
KR102822365B1
KR102822365B1 KR1020247012842A KR20247012842A KR102822365B1 KR 102822365 B1 KR102822365 B1 KR 102822365B1 KR 1020247012842 A KR1020247012842 A KR 1020247012842A KR 20247012842 A KR20247012842 A KR 20247012842A KR 102822365 B1 KR102822365 B1 KR 102822365B1
Authority
KR
South Korea
Prior art keywords
composition
muscle
size
urolithin
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247012842A
Other languages
English (en)
Korean (ko)
Other versions
KR20240060826A (ko
Inventor
페넬로페 안드레욱
크리스토퍼 린슈
빌리엄 블랑코-보제
Original Assignee
아마젠티스 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아마젠티스 에스에이 filed Critical 아마젠티스 에스에이
Publication of KR20240060826A publication Critical patent/KR20240060826A/ko
Application granted granted Critical
Publication of KR102822365B1 publication Critical patent/KR102822365B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247012842A 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물 Active KR102822365B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1515387.7 2015-08-28
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds
KR1020187007291A KR102660005B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007291A Division KR102660005B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물

Publications (2)

Publication Number Publication Date
KR20240060826A KR20240060826A (ko) 2024-05-08
KR102822365B1 true KR102822365B1 (ko) 2025-06-17

Family

ID=54326542

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247012842A Active KR102822365B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물
KR1020187007291A Active KR102660005B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187007291A Active KR102660005B1 (ko) 2015-08-28 2016-08-26 유로리틴 화합물을 포함하는 조성물

Country Status (15)

Country Link
US (4) US10695320B2 (https=)
EP (1) EP3340977B1 (https=)
JP (3) JP7227003B2 (https=)
KR (2) KR102822365B1 (https=)
CN (1) CN108289879A (https=)
AU (1) AU2016314987B2 (https=)
BR (1) BR112018003745B1 (https=)
CA (1) CA2996724C (https=)
ES (1) ES2936723T3 (https=)
GB (1) GB201515387D0 (https=)
MX (1) MX2018002543A (https=)
PT (1) PT3340977T (https=)
RU (1) RU2754761C2 (https=)
SG (1) SG10202001793PA (https=)
WO (1) WO2017036992A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6054301B2 (ja) * 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
DK4233858T3 (da) 2012-06-27 2025-05-12 Amazentis Sa Forbedring af autofagi eller forøgelse af levetiden ved indgivelse af urolithiner eller forstadier til disse
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
US20180256538A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Method for improving mitophagy in subjects
CA3100335A1 (en) 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
WO2022113693A1 (ja) * 2020-11-30 2022-06-02 国立研究開発法人産業技術総合研究所 筋ジストロフィー治療剤、中心静脈栄養用組成物、筋組織の炎症抑制剤および筋ジストロフィーの抗炎症用食品組成物
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
CA3206062A1 (en) 2021-01-27 2022-08-04 Said Oumouch Urolithin derivatives and methods of use thereof
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
WO2023199908A1 (ja) * 2022-04-11 2023-10-19 株式会社ダイセル 乳化組成物の製造方法
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
EP4642448A1 (en) * 2022-12-27 2025-11-05 Indian Institute of Science A method for the treatment of epilepsy
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
KR20250158913A (ko) 2024-04-30 2025-11-07 주식회사 파이안바이오테크놀로지 유로리틴을 함유하는 탈모완화제와 모발성장촉진제
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097231A1 (en) * 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
BR9708248A (pt) 1996-03-26 1999-07-27 Lilly Co Eli Benzotiofenos formulações contendo os mesmos e metódos
WO1999053941A1 (fr) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Preparations orales contenant des derives de trh
CA2363123C (en) 1999-02-22 2011-09-06 Kenneth Iain Cumming Solid oral dosage form containing an enhancer
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
WO2006035900A1 (ja) 2004-09-29 2006-04-06 San-Ei Gen F.F.I., Inc. コエンザイムｑ１０含有乳化組成物
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2145904A1 (de) 2008-07-18 2010-01-20 Basf Se Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
PT2547205T (pt) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Novos métodos para atingir células estaminais cancerígenas
EP2550092B1 (de) 2010-03-22 2018-08-15 Instillo GmbH Verfahren zur herstellung von mikro- oder nanopartikeln
WO2011131943A2 (en) 2010-04-20 2011-10-27 Cipla Limited Pharmaceutical compositions
US20140107100A1 (en) 2010-11-24 2014-04-17 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンｃ経口投与用組成物
JP6054301B2 (ja) * 2010-12-23 2017-01-11 アマゼンティス エスアーＡｍａｚｅｎｔｉｓ Ｓａ ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
CA2826884A1 (en) * 2012-09-14 2014-03-14 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015097231A1 (en) * 2013-12-24 2015-07-02 Amazentis Sa Prodrugs of urolitihns and uses thereof

Also Published As

Publication number Publication date
BR112018003745A2 (pt) 2018-09-25
KR102660005B1 (ko) 2024-04-22
JP7227003B2 (ja) 2023-02-21
PT3340977T (pt) 2023-01-31
US10695320B2 (en) 2020-06-30
AU2016314987A1 (en) 2018-03-29
CN108289879A (zh) 2018-07-17
JP2022177130A (ja) 2022-11-30
RU2018108136A3 (https=) 2020-01-31
SG10202001793PA (en) 2020-04-29
WO2017036992A1 (en) 2017-03-09
HK1257500A1 (en) 2019-10-25
US11925616B2 (en) 2024-03-12
MX2018002543A (es) 2018-06-15
US20200323818A1 (en) 2020-10-15
US20220323407A1 (en) 2022-10-13
RU2754761C2 (ru) 2021-09-07
KR20180037052A (ko) 2018-04-10
ES2936723T3 (es) 2023-03-21
US11337957B2 (en) 2022-05-24
AU2016314987B2 (en) 2021-07-08
JP2018533618A (ja) 2018-11-15
RU2018108136A (ru) 2019-09-30
GB201515387D0 (en) 2015-10-14
BR112018003745B1 (pt) 2023-11-07
US20240148690A1 (en) 2024-05-09
EP3340977A1 (en) 2018-07-04
US20180243261A1 (en) 2018-08-30
KR20240060826A (ko) 2024-05-08
JP2025004129A (ja) 2025-01-14
CA2996724A1 (en) 2017-03-09
EP3340977B1 (en) 2022-11-02
CA2996724C (en) 2024-05-21

Similar Documents

Publication Publication Date Title
US11925616B2 (en) Compositions comprising urolithin compounds
CN102348469B (zh) 富含omega-3的水包鱼油非口服营养乳状液
JP6775419B2 (ja) 末梢神経障害の予防又は改善用組成物
JP6675413B2 (ja) トコトリエノールを効果的に送達するための製剤
EP2432328A1 (en) Fat blends and uses thereof
HK1257500B (en) Compositions comprising urolithin compounds
AU2021249347A1 (en) Composition for improving friendliness and/or empathetic capacity
US20200085774A1 (en) Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
JP2026501988A (ja) ウロチリンとケトン体との組み合わせ
EP3135279A1 (en) Unsaturated fatty acid absorption accelerator
CN110755393A (zh) 一种赖诺普利滴剂及其制备方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240418

Application number text: 1020187007291

Filing date: 20180313

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240517

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240705

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250314

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250613

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250613

End annual number: 3

Start annual number: 1

PG1601 Publication of registration